$24.92
0.23[0.93%]
At close: Apr 19
$24.92
0[0.00%]
After Hours: 4:15PM EDT
PTC Therapeutics
(NASDAQ:PTCT)PTC Therapeutics Stock (NASDAQ:PTCT), Analyst Ratings, Price Targets, Predictions
PTC Therapeutics Inc has a consensus price target of $36.06, established from looking at the 80 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Jefferies, and RBC Capital on April 12, 2024, March 20, 2024, and March 8, 2024. With an average price target of $36 between Cantor Fitzgerald, Jefferies, and RBC Capital, there's an implied 44.46% upside for PTC Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Jefferies
RBC Capital
TD Cowen
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for PTC Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/12/2024 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 80.58% | Cantor Fitzgerald | Kristen Kluska | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 40.45% | Jefferies | Kelly Shi | $33 → $35 | Maintains | Buy | Get Alert |
| 03/08/2024 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 12.36% | RBC Capital | Brian Abrahams | → $28 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/01/2024 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 12.36% | RBC Capital | Brian Abrahams | $22 → $28 | Maintains | Sector Perform | Get Alert |
| 03/01/2024 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 80.58% | Cantor Fitzgerald | Kristen Kluska | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/01/2024 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 20.39% | TD Cowen | Joseph Thome | $32 → $30 | Maintains | Market Perform | Get Alert |
| 01/26/2024 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 80.58% | Cantor Fitzgerald | Kristen Kluska | $51 → $45 | Maintains | Overweight | Get Alert |
| 01/26/2024 | PTCT | Buy Now | PTC Therapeutics | $24.92 | -11.72% | RBC Capital | Brian Abrahams | $27 → $22 | Maintains | Sector Perform | Get Alert |
| 12/19/2023 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 12.36% | Morgan Stanley | Jeffrey Hung | → $28 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 12/18/2023 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 104.65% | Cantor Fitzgerald | Kristen Kluska | → $51 | Reiterates | Overweight → Overweight | Get Alert |
| 11/20/2023 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 104.65% | Cantor Fitzgerald | Kristen Kluska | → $51 | Reiterates | Overweight → Overweight | Get Alert |
| 10/27/2023 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 12.36% | Morgan Stanley | Jeffrey Hung | $31 → $28 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 0.32% | Barclays | Gena Wang | $26 → $25 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | PTCT | Buy Now | PTC Therapeutics | $24.92 | -31.78% | Citigroup | David Lebovitz | $29 → $17 | Downgrade | Neutral → Sell | Get Alert |
| 10/06/2023 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 0.32% | Truist Securities | Robyn Karnauskas | → $25 | Downgrade | Buy → Hold | Get Alert |
| 09/19/2023 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 80.58% | Truist Securities | Barry Jonas | → $45 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2023 | PTCT | Buy Now | PTC Therapeutics | $24.92 | -7.7% | B of A Securities | Tazeen Ahmad | $43 → $23 | Maintains | Underperform | Get Alert |
| 09/18/2023 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 80.58% | Truist Securities | Barry Jonas | $60 → $45 | Maintains | Buy | Get Alert |
| 09/18/2023 | PTCT | Buy Now | PTC Therapeutics | $24.92 | 4.33% | Barclays | Gena Wang | $44 → $26 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for PTC Therapeutics (PTCT)?
The latest price target for PTC Therapeutics (NASDAQ: PTCT) was reported by Cantor Fitzgerald on April 12, 2024. The analyst firm set a price target for $45.00 expecting PTCT to rise to within 12 months (a possible 80.58% upside). 50 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for PTC Therapeutics (PTCT)?
The latest analyst rating for PTC Therapeutics (NASDAQ: PTCT) was provided by Cantor Fitzgerald, and PTC Therapeutics reiterated their overweight rating.
When was the last upgrade for PTC Therapeutics (PTCT)?
There is no last upgrade for PTC Therapeutics.
When was the last downgrade for PTC Therapeutics (PTCT)?
The last downgrade for PTC Therapeutics Inc happened on December 19, 2023 when Morgan Stanley changed their price target from N/A to $28 for PTC Therapeutics Inc.
When is the next analyst rating going to be posted or updated for PTC Therapeutics (PTCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PTC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PTC Therapeutics was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
Is the Analyst Rating PTC Therapeutics (PTCT) correct?
While ratings are subjective and will change, the latest PTC Therapeutics (PTCT) rating was a reiterated with a price target of $0.00 to $45.00. The current price PTC Therapeutics (PTCT) is trading at is $24.92, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.